H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Celcuity Inc (CELC) today and set a price target of $36. The company’s shares closed on Friday at $23.93.
Selvaraju noted:
“Our price target is derived from a market value of the firm at $369M, which includes a discounted cash flow based asset value for CELx tests, with a 15% discount rate and 0.5% terminal growth rate. Probabilities of success assigned are 45% and 10% for breast cancer and colon cancer, respectively. Risks include, but are not limited to: (1) failure of CELx tests in clinical trials; (2) failure of CELx tests to secure CDx regulatory approval; and (3) failure of CELx tests to achieve commercial success due to market size, penetration rate, and/or competition.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Celcuity Inc is a Moderate Buy with an average price target of $36.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31 and a one-year low of $13.16. Currently, Celcuity Inc has an average volume of 14.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celcuity, Inc. is cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies.
